Cargando…
SAT-091 Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
Background: Ruxolitinib is a JAK1/2 inhibitor that is FDA approved to treat certain myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). The JAK family kinases are targeted in cancers due to their role in cytokine receptor signal transduction, and are also ke...
Autores principales: | Sapre, Manali, Tremblay, Douglas, Leiter, Amanda, Coltoff, Alexander, Geevarghese, Anita, Mascarhenas, John, Gallagher, Emily |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552330/ http://dx.doi.org/10.1210/js.2019-SAT-091 |
Ejemplares similares
-
SAT-094 Overweight and Obesity Associated with Immune-Related Adverse Events in Patients on Immune Checkpoint Inhibitor Therapy
por: Leiter, Amanda, et al.
Publicado: (2019) -
SUN-091 Functional Links between ADP-Ribosylation and Phosphorylation on Histone H2B Regulate Adipocyte Differentiation
por: Huang, Dan, et al.
Publicado: (2019) -
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019) -
MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Haider, Karim, et al.
Publicado: (2019) -
SAT-585 Autoregulation of Adipose Tissue Development
por: Feldman, Brian, et al.
Publicado: (2020)